Market Cap | 13.51M | P/E | - | EPS this Y | 82.50% | Ern Qtrly Grth | - |
Income | -15.44M | Forward P/E | 2.97 | EPS next Y | 60.70% | 50D Avg Chg | 3.00% |
Sales | 52.57M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -30.00% |
Dividend | N/A | Price/Book | 0.55 | EPS next 5Y | - | 52W High Chg | -88.00% |
Recommedations | 2.00 | Quick Ratio | 0.58 | Shares Outstanding | 13.39M | 52W Low Chg | 71.00% |
Insider Own | 36.09% | ROA | -7.15% | Shares Float | 8.56M | Beta | 1.80 |
Inst Own | 8.15% | ROE | -43.18% | Shares Shorted/Prior | 42.09K/147.50K | Price | 1.01 |
Gross Margin | 22.08% | Profit Margin | -74.64% | Avg. Volume | 58,998 | Target Price | - |
Oper. Margin | -18.26% | Earnings Date | Mar 28 | Volume | 121,119 | Change | 12.21% |
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.